Skip to main content
Global
Global Fin Swe Nor Den Ger Cze Svk Pol Hun Nld Bel (nl) Bel (fr) USA
Log in
  • Aidian – Your aid in diagnostics
  • Products
  • About us
  • News
  • Antimicrobial resistance
  • Aidian Academy
  • Customer stories
  • Events
  • For distributors / Log in
Contact us Search
Logo
Contact us
  • Point of care
  • Microbiology
  • Molecular diagnostics
  • Hygiene monitoring
  • RIA / Collagens
  • Respiratory tract infections
  • Products available in the USA
Point of care
  • QuikRead go system
  • QuikRead 101
Read more
QuikRead go
  • QuikRead go Plus Instrument
  • QuikRead go Instrument
  • QuikRead go easy CRP
  • QuikRead go CRP
  • QuikRead go CRP+Hb
  • QuikRead go wrCRP
  • QuikRead go wrCRP+Hb
  • QuikRead go HbA1c
  • QuikRead go Strep A
  • QuikRead go iFOBT
  • QuikRead go accessories
QuikRead go
Microbiology
  • Uricult
  • Uricult Vet
  • Cultura M
Read more
Molecular diagnostics
  • SIBA
Read more
SIBA licensing and partnering opportunities
Read more
Hygiene monitoring
  • Easicult
  • Hygicult
  • Clean Card PRO
Read more
NEW! A comprehensive guide to monitoring surface hygiene now published
Read more
RIA / Collagens
  • UniQ
Read more
  • Our history
  • Board and management
  • Sustainability
  • Culture
  • Careers
  • Employee stories
  • Partnering and licensing
  • UN Global Compact Commitment | Aidian
  • News
  • Product news
  • AMR
  • Events
  • Stories from customers
  • COVID-19
  • About C-reactive protein (CRP)
  • AMR interview
  • CRP and lower respiratory tract infections
  • Educational materials
  • QuikRead go CRP products
  • Spreading of antibiotic resistant bacteria
  • Useful links
  • Generally
  • Product information
  • Courses
  • Documents and materials
  • Frequently asked questions
  • Sleeping hygiene: monitoring cleanliness of pillows and bedding
Logo
Contact us Close
  • Products
    • Point of care
      • QuikRead go system
      • QuikRead 101
    • Microbiology
      • Uricult
      • Uricult Vet
      • Cultura M
    • Molecular diagnostics
      • SIBA
    • Hygiene monitoring
      • Easicult
      • Hygicult
      • Clean Card PRO
    • RIA / Collagens
      • UniQ
    • Respiratory tract infections
    • Products available in the USA
  • About us
    • Our history
    • Board and management
    • Sustainability
    • Culture
    • Careers
    • Employee stories
    • Partnering and licensing
    • UN Global Compact Commitment | Aidian
  • News
    • News
    • Product news
    • AMR
    • Events
    • Stories from customers
    • COVID-19
  • Antimicrobial resistance
    • About C-reactive protein (CRP)
    • AMR interview
    • CRP and lower respiratory tract infections
    • Educational materials
    • QuikRead go CRP products
    • Spreading of antibiotic resistant bacteria
    • Useful links
  • Aidian Academy
    • Generally
    • Product information
    • Courses
    • Documents and materials
    • Frequently asked questions
  • Customer stories
    • Sleeping hygiene: monitoring cleanliness of pillows and bedding
  • Events
  • For distributors / Log in
Popular products
QuikRead go Plus Instrument

QuikRead go Plus Instrument

QuikRead go HbA1c

QuikRead go HbA1c

SIBA

SIBA

Latest news
View all

New Study on QuikRead go easy CRP supports the use of CRP-based scoring to improve neonatal infection management in low-resource settings

May 22, 2025 | News, Product news

May 5 is World Hand Hygiene Day

May 5, 2025 | News, Product news

Meet us at EuroMedLab 2025!

April 29, 2025 | Events

  • View all
  • No results found
  • Loading...
News

New Study on QuikRead go easy CRP supports the use of CRP-based scoring to improve neonatal infection management in low-resource settings

May 22, 2025 | News, Product news

May 5 is World Hand Hygiene Day

May 5, 2025 | News, Product news

Back to all news
November 29, 2023
News,
Product news

Benefits of Bladder EpiCheck for bladder cancer surveillance

As November, Bladder Health Month 2023, is coming to an end we want to highlight Bladder Cancer surveillance.

Bladder cancer is the 5th most common cancer in Europe, affecting over 200 000 people yearly.1 Non-muscle-invasive bladder cancer (NMIBC) accounts for the majority of newly diagnosed bladder cancers. With up to 70% of patients experiencing recurrence within 2 years of initial treatment and 10-15% progressing to higher risk cancer, monitoring of bladder cancer is vital.2

The current gold standard methods for bladder cancer surveillance are cystoscopy and cytology. However, they have their limitations as both are based on operator-dependent assessment. Cytology has low to moderate sensitivity, while some types of tumours are easily missed in cystoscopy.2

During the first years after initial treatment, bladder cancer patients undergo as many as 4 cystoscopies a year. Cystoscopy is an invasive and expensive procedure, so the need for an effective biomarker test for surveillance is high.

Bladder EpiCheck® from Nucleix is a urine marker test for monitoring of NMIBC. It uses a panel of 15 DNA methylation markers and is included in the EAU (European Association of Urology) guidelines for bladder cancer surveillance. The guidelines state that Bladder EpiCheck could be used to replace and/or postpone cystoscopy.3

Bladder EpiCheck

A meta-analysis of the diagnostic accuracy of urinary biomarker tests found that Bladder EpiCheck has a high-grade Negative Predictive Value (NPV) of 99 %, high-grade sensitivity of 91 % and specificity of 84 %.4

The results of the test are objective and not affected by BCG treatment, hematuria, or infections.5 The high performance of the test makes it a reliable tool to rule out high-risk recurrence and reduce unnecessary procedures.

Reducing the number of cystoscopies by incorporating Bladder EpiCheck into the surveillance of bladder cancer could lessen the strain on the healthcare system as well as benefit the well-being of patients.

For more detailed information about Bladder EpiCheck, head to the product site through links below or contact us.

  • Bladder EpiCheck (Finland)
  • Bladder EpiCheck (Sweden)
  • Bladder EpiCheck (Norway)
  • Bladder EpiCheck (Denmark)

Aidian is the proud distributor of Bladder EpiCheck in the Nordics.


References

  1. European Association of Urology. Bladder Cancer: The Forgotten Cancer. https://uroweb.org/news/bladder-cancer-the-forgotten-cancer. Accessed 27.11.2023.
  2. Biomarkers in the management of non-muscle invasive bladder cancer (NMIBC), BCaMonitor, Updated May 2023.
  3. EAU Non-muscle-invasive Bladder Cancer guidelines 2022. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/diagnosis
  4. Laukhtina et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2021 Dec;4(6):927-942; and corrigendum at Eur Urol Oncol. 2022 Jan 19;S2588-9311(22)00004-9.
  5. Cochetti et al. Urol Onc Nov 2021; Pierconti et al. Urol Onc Nov 2021, Bladder EpiCheck® EU Instructions For Use, 09-May-2022


Share
Facebook
Twitter
Email

Aidian Oy

Koivu-Mankkaan tie 6 B,
FI-02200 Espoo,
Finland

P.O. Box 83,
FI-02101 Espoo,
Finland

+358 10 309 3000
Company
  • About us
  • Careers
  • Contact us
  • Events
  • Product-specific inquiries
  • Sales support
  • Sales related inquiries
  • Sustainability
Products
  • Point of care
  • Microbiology
  • Molecular diagnostics
  • Hygiene monitoring
  • RIA / Collagens
  • Respiratory tract infections
Quick links
  • Aidian Academy
  • Aidian Connect
  • IFU Revision histories
Copyright © 2025 Aidian
  • Privacy Policy
  • Privacy Statements
  • Cookie Policy
  • Social Media Policy